Study was carried out on 80 mechanical energy menorrhagia patients under 18 years of age, treated with rigevidon combined with preventive antibiotics and commonly drugs as oxytoxine, ecgometrine at the Newborn & Mother Protection Hospital in 2000. The results showed that: with single dose of 2 tablets per day, taken in unique time in the evening, and then reduction of dose to 1 tablet per day when bleeding stopped, to make a 28 days menstruation cycle, the good efficacy was observed in 96.25% of patients (77 patients respond well to treatment). After, maintain treatment for 3 months following to make an artificial menstruation cycle then stop completely. All of patients had no any seriously complications, including menorrhagia after stopping treatment
Menorrhagia ; Therapeutics

A study on 216 patients who had endometrial hyperplasia, these patients had been examined and treated from June 1999 to June 2004 at National hospital of Obstetrics and Gynecology. The patients were divided into 2 groups: Group 1 included 108 patients who were given Orgametril 5mgx 2 tablets/day; group 2 included 108 patients who received only consultation and follow up 6 months after being endometrium curetted. Results: After 6 months of treatment with progestin (Orgametril), there were only 3 patients in group 1 had pathological signs of endometrial hyperplasia (2.8%); 94 patients recovered completely (87%). In group 2, there were 74 patients recovered completely (64.8%) and 19 patients had pathological signs of endometrial hyperplasia (17.6%). After being treated, old patients had endometrium changed into menopause stage: atrophy, thinner and stop working, they also did not have menorrhagia anymore.
Menorrhagia ; Endometrial Hyperplasia ; Therapeutics

Objective: To detail the experience and evaluate the effectiveness of hysteroscopy in the Philippine General Hospital. Setting: Tertiary care center Study population: All available records of patients admitted for hysteroscopy from July 1996 to December 2000. Results: There were 240 records available for review with a mean patient age of 39.4 +/- 14.2 years (range 15-75). There was an increasing number of hysteroscopy cases, especially operative cases performed through the years. Bleeding was the most common complaint. Indications for hysteroscopy were: endometrial mass (49 percent), abnormal uterine bleeding (16 percent), infertility (10 percent), and thickened endometrium (7 percent). There were 6 cases of lost IUD. A total of 58.7 percent intracavitary abnormalities were noted during hysteroscopy and were observed in the following subgroups: 65.7 percent in those with premenopausal bleeding, 46.7 percent in those with postmenopausal bleeding, 28.9 percent in infertility, and 74.5 percent with the diagnosis of an intracavitary mass. Conclusion: A summary of hysteroscopy cases done at a tertiary care center in the Philippines was presented. This review demonstrates the utility of hysteroscopy in the diagnosis of intracavitary abnormalities and in the removal of IUDs.
HYSTEROSCOPY ; UTERINE HEMORRHAGE ; MENORRHAGIA

Ovarian fibrothecoma is a relatively new term that is used to describe an ovarian sex cord stromal tumour that has mixed features of both fibroma and thecoma. The prevalence of ovarian fibrothecoma tumours is very rare and is reported to be about 1.2% of all ovarian tumours. We report a case of a 32-year-old woman who presented with acute menorrhagia with no previous medical, surgical or gynecological history. She was amenorrhic for four years after the insertion of a levonorgestrelreleasing intrauterine system (LNG-IUS) for contraception. The efficacy and location of LNG-IUS was reflected due to the sudden onset of menorrhagia. On pelvic examination and ultrasound the LNG-IUS could not be visualized and a uterine fibroid was noted. A diagnostic laparoscopy was done to identify the LNG-IUS, which revealed an incidental large ovarian mass on the left ovary. CA-125 level was elevated to 45 kU/L (Normal range <35 kU/L). Total abdominal hysterectomy, left salpingo-oopherectomy and cystectomy were performed. On histopathology, the mass was proven to be an ovarian fibrothecoma. No signs of malignancy were noted on peritoneal fluid cytology. The LNG-IUS was found inside the uterus. Our case is reported on the basis of the rare incidence of ovarian fibrothecoma and the possible effect it may have on the efficacy of LNG-IUS causing menorrhagia.
Menorrhagia ; Fibroma ; Thecoma ; Ovarian Neoplasms

Study on 80 symptomatic menorrhagia patients less than 18 years old treated at Institute for Protection of Mother and Newborn in the year 2000. Results: the rate of patients with irregular menstruation was highest (38.75%). 70% of patients lived in rural, so the rate of late hospital admission (>15 days) accounted for 73.75%. All patients suffered from anemia with 82.5% patients with moderate and severe anemia. Treatment with 2 tablets Rigevidon a day only one time in the evening until menorrhagia reduces, follows by 1 tablet a day for making artificial menstruation of 28 days, is effective in 96.25% patients. This finding showed that using Rigevidon for treating pubertal menorrhagia is simple, safe, and effective, no significant complication.
Menorrhagia ; Ethinyl Estradiol-Norgestrel Combination ; Therapeutics

Sclerosing stromal tumor of the ovary is a rare benign neoplasm, with distinctive clinical and pathologic features. It occurs predominantly in females during the second and third decades of life. Histologically, it is composed of cellular and acellular collagenized areas, and edematous stromal areas, and at ultrasonography and computed tomography is seen as a distinctive mixed solid and cystic mass lesion. We report a case of sclerosing stromal tumor of the ovary in a 15-year-old girl with a history of menorrhagia since menarche. Ultrasonography revealed the tumor as a well-defined, lobulated, heterogenous echogenic pelvic mass, while at CT, a huge pelvic mass 9x9x10 cm in size, was seen. This comprised a well-enhanced internal solid portion, a capsule, septa, and a non-enhanced cystic portion.
Adolescent ; Collagen ; Female ; Humans ; Menarche ; Menorrhagia ; Ovary* ; Ultrasonography

OBJECTIVE: To evaluate the clinical results of radiofrequency (RF) myolysis on uterine myomas for 1 year after the procedure. METHODS: 56 women with symptomatic uterine myomas underwent RF myolysis at Chosun University hospital between January 2006 and December 2006. The study group designed by 22 women who were followed up for 1 year after the procedure. Preoperatively, by using ultrasonography, size, numbers, location and volume of uterine myomas were checked and hemoglobin and subjective symptoms were checked. 3 months, 6 months, 9months and 12months after the procedure, the size and volume of uterine myomas were measured by same examiner. And also the symptoms caused by uterine myomas were observed. RESULTS: The average age of the patients was 43.0 years. The average maximal diameter of uterine myoma was 5.7+/-1.9 cm, the average volume was 83.2+/-67.6 cm3, and the average hemoglobin was 11.5+/-2.0 mg/dL. 3 months, 6 months, 9 months and 12 months after the procedure, the average maximal diameters of the uterine myomas were decresed by 4.7+/-1.8 cm, 4.4+/-1.6 cm, 4.3+/-1.7 cm, 3.9+/-1.6 cm and the average volume was decreased by 49.5+/-46.5 cm3, 41.1+/-43.2 cm3, 40.5+/-43.7 cm3, 30.8+/-34.6 cm3 respectively, and the average hemoglobin was 11.8+/-1.8 mg/dL, 11.9+/-1.8 mg/dL, 12.1+/-1.7 mg/dL, 12.1+/-1.5 mg/dL. After the procedure, 81.3%, 84.8%, 87.0%, 86.4% of the group had improvement of the symptoms (dysmenorrhea, hypermenorrhea, pelvic pain) respectively. CONCLUSION: RF myolysis had effects on reduction of the size of uterine myomas and improvement of the symptoms. RF myolysis would be a useful alternative treatment of uterine myomas with preserving the uterus.
Female ; Follow-Up Studies ; Hemoglobins ; Humans ; Menorrhagia ; Myoma

OBJECTIVE: to test the safety of ultrasound imaging guided high intensity focused ultrasound (HIFU) to ablate uterine myoma. METHODS: From September 2008 to February 2009, patients with dysmenorrhea and/or menorrhagia for uterine myomas had been enrolled. HIFU ablation was performed at 1 MHz. 400 W/cm2 of pulses were delivered for 150 m second with 150 m second interval at the target point for 70 cycles. This process was repeated on a point by point basis. After one slice was treated, the target was shifted 4 mm laterally. If patient were complaining of pain, the procedures were stopped for a while. RESULTS: The distribution of age was 29~48 years old, and of longest diameter was 36.0~115.0 mm, and of target distance from skin was 55~100 mm, and of number of treatment was 2~6. Nobody gave up the procedure for pain or any other reason. The procedures took 40 to 60 minutes for a slice. One or three slices were treated in a day. All patients went home after HIFU without medication. Nobody reported any clinically severe complications. Everybody returned to normal activities 1 day after the procedure. Nobody complained of vaginal spotting after one cycle of menstruation. CONCLUSION: Ultrasound imaging-guided HIFU treatment appears to be safe to ablate the uterine myomas.
Dysmenorrhea ; Female ; Humans ; Menorrhagia ; Menstruation ; Metrorrhagia ; Myoma ; Skin

OBJECTIVE: This study was designed to evaluate the patterns of menstruation including menorrhagia using menstrual index, to find out correlations between patient's own judgement and actual patterns of menstruation in Korean women, and to develop the menstrual diary using menstrual index as a screening of menstrual disorders. METHODS: Seventy-seven women teachers of elementary school undergoing routine health screening test were asked to complete a pictorial blood loss assessment chart and a set of interview sheets regarding menstrual history and their subjective judgement on their amount of menstruation. Spearman correlation test was used to assess the correlation between menstrual index which was obtained from pictorial chart and serum hemoglobin concentration. RESULTS: The mean menstrual intervals were 29.8 days (SD+/-5.1), the mean menstrual duration was 5.6 days (SD+/-1.3), the mean value of menstrual index was 170.3 (SD+/-89.2) which varied from 12 to 411, the mean serum hemoglobin concentration was 12.3 g/dL. Significant correlation was found between the serum hemoglobin concentration and the menstrual index (r=-0.29, p=0.01). Seventeen of 20 women who had anemia (serum hemoglobin concentration below 12.0 g/dL) and 25 of 26 women who had menorrhagia (menstrual index above 200) considered her menstruation as 'normal'. CONCLUSION: Many women who have anemia due to menorrhagia are not aware of the serious consequences of menorrhagia. Writing a 'menstrual diary' using menstrual index would be easier and more practical method in predicting menorrhagia.
Anemia ; Female ; Humans ; Mass Screening ; Menorrhagia ; Menstruation ; Writing

OBJECTIVE: To analyze the clinical experiences of patients who treated with levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis associated with dysmenorrhea and/or menorrhagia. METHODS: The LNG-IUS was inserted into 103 patients who were diagnosed with adenomyosis on ultrasound examination and suffered from dysmenorrhea or menorrhagia at CHA Gangnam Medical Center between January 2009 and December 2009. Symptomatic changes of dysmenorrhea and menorrhagia, side effects, and failure rates were evaluated, retrospectively. RESULTS: During the follow-up periods, dysmenorrhea was improved in 91.4% and menorrhagia was improved in 90.4% of patients. Most common side effects were prolonged vaginal spotting in 41 (39.8%), and expulsion of LNG-IUS in 32 (31.1%) patients. Six (5.7%) patients were premature removal of LNG-IUS and 9 (8.5%) patients were underwent hysterectomy. Overall 77 (74.8%) patients continued to use of LNG-IUS. CONCLUSION: The LNG-IUS is effective treatment option for management of dysmenorrhea and menorrhagia for patients with clinical diagnosis of adenomyosis. It seemed to be an alternative treatment method before hysterectomy.
Adenomyosis ; Dysmenorrhea ; Female ; Follow-Up Studies ; Humans ; Hysterectomy ; Menorrhagia ; Metrorrhagia